Cowen & Co. Initiates Coverage of Bruker with Outperform Rating | GenomeWeb

NEW YORK (GenomeWeb News) – Cowen & Co. today started covering Bruker, giving it an Outperform rating and a $21 price target.

In a research report, analyst Doug Schenkel said that while Bruker has challenges ahead and near-term catalysts for its shares are not obvious, "we are enthused about the long-term potential and associated unlocking of significant value; we view the risk/reward as very compelling for investors with an 18-24 month investment horizon."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: peanut subgenome progenitor sequence, homozygosity mapping and linkage analyses using exome data, and more.

Tech companies like Microsoft are looking into DNA as a data storage device, Scientific American writes.

The New York Times writes that the Max Planck Institute for Infection Biology's Emmanuelle Charpentier has always been on the move, though now it's more about CRISPR.

The European Union calls for all publicly funded scientific papers to be immediately freely accessible to the public by 2020.